

Dan Greenberg

List of Publications by Citations

Source: <https://exaly.com/author-pdf/5630468/dan-greenberg-publications-by-citations.pdf>

Version: 2024-04-17

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

119
papers

5,231
citations

28
h-index

71
g-index

135
ext. papers

6,503
ext. citations

3
avg. IF

5.23
L-index

#	Paper	IF	Citations
119	Consolidated Health Economic Evaluation Reporting Standards (CHEERS)--explanation and elaboration: a report of the ISPOR Health Economic Evaluation Publication Guidelines Good Reporting Practices Task Force. <i>Value in Health</i> , 2013 , 16, 231-50	3.3	1264
118	Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statement. <i>BMJ, The</i> , 2013 , 346, f1049	5.9	659
117	Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statement. <i>Value in Health</i> , 2013 , 16, e1-5	3.3	381
116	Bias in published cost effectiveness studies: systematic review. <i>BMJ, The</i> , 2006 , 332, 699-703	5.9	274
115	Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statement. <i>Cost Effectiveness and Resource Allocation</i> , 2013 , 11, 6	2.4	230
114	Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statement. <i>International Journal of Technology Assessment in Health Care</i> , 2013 , 29, 117-22	1.8	191
113	Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statement. <i>BMC Medicine</i> , 2013 , 11, 80	11.4	151
112	When is cancer care cost-effective? A systematic overview of cost-utility analyses in oncology. <i>Journal of the National Cancer Institute</i> , 2010 , 102, 82-8	9.7	141
111	Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statement. <i>European Journal of Health Economics</i> , 2013 , 14, 367-72	3.6	136
110	Growth and quality of the cost-utility literature, 1976-2001. <i>Value in Health</i> , 2005 , 8, 3-9	3.3	114
109	Trends in the measurement of health utilities in published cost-utility analyses. <i>Value in Health</i> , 2006 , 9, 213-8	3.3	102
108	When is critical care medicine cost-effective? A systematic review of the cost-effectiveness literature. <i>Critical Care Medicine</i> , 2006 , 34, 2738-47	1.4	94
107	The costs and cost-effectiveness of an integrated sepsis treatment protocol. <i>Critical Care Medicine</i> , 2008 , 36, 1168-74	1.4	91
106	Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statement. <i>Pharmacoeconomics</i> , 2013 , 31, 361-7	4.4	90
105	Can we afford to eliminate restenosis? Can we afford not to?. <i>Journal of the American College of Cardiology</i> , 2004 , 43, 513-8	15.1	82
104	Is the United States ready for QALYs?. <i>Health Affairs</i> , 2009 , 28, 1366-71	7	57
103	Trajectories of Injectable Cancer Drug Costs After Launch in the United States. <i>Journal of Clinical Oncology</i> , 2018 , 36, 319-325	2.2	55

102	Much cheaper, almost as good: decrementally cost-effective medical innovation. <i>Annals of Internal Medicine</i> , 2009 , 151, 662-7	8	53
101	Is burnout associated with referral rates among primary care physicians in community clinics?. <i>Family Practice</i> , 2014 , 31, 44-50	1.9	49
100	Costs and resource utilization for diagnosis and treatment during the initial year in a European inflammatory bowel disease inception cohort: an ECCO-EpiCom Study. <i>Inflammatory Bowel Diseases</i> , 2015 , 21, 121-31	4.5	42
99	Twenty years of cost-effectiveness analysis in medical imaging: are we improving?. <i>Radiology</i> , 2008 , 249, 917-25	20.5	37
98	Consolidated Health Economic Evaluation Reporting Standards (CHEERS) 2022 Explanation and Elaboration: A Report of the ISPOR CHEERS II Good Practices Task Force.. <i>Value in Health</i> , 2022 , 25, 10-31	3.3	35
97	Drug-eluting stent task force: final report and recommendations of the working committees on cost-effectiveness/economics, access to care, and medicolegal issues. <i>Catheterization and Cardiovascular Interventions</i> , 2004 , 62, 1-17	2.7	34
96	Can we better prioritize resources for cost-utility research?. <i>Medical Decision Making</i> , 2005 , 25, 429-36	2.5	34
95	Cost-utility analyses of diagnostic laboratory tests: a systematic review. <i>Value in Health</i> , 2011 , 14, 1010-8	3.3	32
94	Costs and cost-effectiveness of carotid stenting versus endarterectomy for patients at increased surgical risk: results from the SAPHIRE trial. <i>Catheterization and Cardiovascular Interventions</i> , 2011 , 77, 463-72	2.7	32
93	Temporal trends in patient characteristics and survival of intensive care admissions with sepsis: a multicenter analysis*. <i>Critical Care Medicine</i> , 2012 , 40, 855-60	1.4	31
92	Nutritional risk and health care use before and after an acute hospitalization among the elderly. <i>Nutrition</i> , 2009 , 25, 415-20	4.8	28
91	Decisions to adopt new technologies at the hospital level: Insights from Israeli medical centers. <i>International Journal of Technology Assessment in Health Care</i> , 2005 , 21, 219-227	1.8	28
90	Overuse of Head CT Examinations for the Investigation of Minor Head Trauma: Analysis of Contributing Factors. <i>Journal of the American College of Radiology</i> , 2017 , 14, 171-176	3.5	25
89	Quality of abstracts of papers reporting original cost-effectiveness analyses. <i>Medical Decision Making</i> , 2005 , 25, 424-8	2.5	25
88	Willingness to pay for avoiding coronary restenosis and repeat revascularization: results from a contingent valuation study. <i>Health Policy</i> , 2004 , 70, 207-16	3.2	23
87	A bibliometric review of cost-effectiveness analyses in the economic and medical literature: 1976-2006. <i>Medical Decision Making</i> , 2010 , 30, 320-7	2.5	21
86	Peer review in publication: factors associated with the full-length publication of studies presented in abstract form at the annual meeting of the Society for Medical Decision Making. <i>Medical Decision Making</i> , 2008 , 28, 938-42	2.5	21
85	In-hospital costs of self-expanding nitinol stent implantation versus balloon angioplasty in the femoropopliteal artery (the VascoCoil Trial). <i>Journal of Vascular and Interventional Radiology</i> , 2004 , 15, 1065-9	2.4	21

84	The process of updating the National List of Health Services in Israel: is it legitimate? Is it fair?. <i>International Journal of Technology Assessment in Health Care</i> , 2009 , 25, 255-61	1.8	20
83	Cost-effective diagnostic cardiovascular imaging: when does it provide good value for the money?. <i>International Journal of Cardiovascular Imaging</i> , 2010 , 26, 605-12	2.5	20
82	Correlates of well-being among caregivers of long-term community-dwelling stroke survivors. <i>International Journal of Rehabilitation Research</i> , 2016 , 39, 326-330	1.8	17
81	Coping strategies, satisfaction with life, and quality of life in Crohn's disease: A gender perspective using structural equation modeling analysis. <i>PLoS ONE</i> , 2017 , 12, e0172779	3.7	16
80	A synthesis of cost-utility analysis literature in infectious disease. <i>Lancet Infectious Diseases</i> , 2005 , 5, 383-91	25.5	15
79	Effect of Social Support on Psychological Distress and Disease Activity in Inflammatory Bowel Disease Patients. <i>Inflammatory Bowel Diseases</i> , 2018 , 24, 1389-1400	4.5	14
78	Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statement. <i>Clinical Therapeutics</i> , 2013 , 35, 356-63	3.5	14
77	Delays in publication of cost utility analyses conducted alongside clinical trials: registry analysis. <i>BMJ</i> , 2004 , 328, 1536-7	5.9	14
76	Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) Statement: Updated Reporting Guidance for Health Economic Evaluations.. <i>Value in Health</i> , 2022 , 25, 3-9	3.3	14
75	Effect of psychosocial stressors on patients with Crohn's disease: threatening life experiences and family relations. <i>European Journal of Gastroenterology and Hepatology</i> , 2016 , 28, 1073-81	2.2	14
74	Patient adherence: a blind spot in cost-effectiveness analyses?. <i>American Journal of Managed Care</i> , 2009 , 15, 626-32	2.1	14
73	Cost-effectiveness of adherence-enhancing interventions: a systematic review. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2016 , 16, 67-84	2.2	13
72	PCSK9 inhibitors may improve cardiovascular outcomes-Can we afford them?. <i>International Journal of Cardiology</i> , 2016 , 220, 242-5	3.2	12
71	Diffusion of published cost-utility analyses in the field of health policy and practice. <i>International Journal of Technology Assessment in Health Care</i> , 2005 , 21, 399-402	1.8	12
70	Examining the economic impact of restenosis: implications for the cost-effectiveness of an antiproliferative stent. <i>Clinical Research in Cardiology</i> , 2002 , 91 Suppl 3, 137-43		11
69	A medicoeconomic review of early intervention with biologic agents in the treatment of inflammatory bowel diseases. <i>ClinicoEconomics and Outcomes Research</i> , 2014 , 6, 431-43	1.7	11
68	The association between adherence to cardiovascular medications and healthcare utilization. <i>European Journal of Health Economics</i> , 2016 , 17, 603-10	3.6	10
67	Differing Relationship of Psycho-Social Variables with Active Ulcerative Colitis or Crohn's Disease. <i>International Journal of Behavioral Medicine</i> , 2018 , 25, 341-350	2.6	10

66	The adoption of cost-effectiveness acceptability curves in cost-utility analyses. <i>Medical Decision Making</i> , 2010 , 30, 314-9	2.5	10
65	Decision making in acquiring medical technologies in Israeli medical centers: a preliminary study. <i>International Journal of Technology Assessment in Health Care</i> , 2003 , 19, 194-201	1.8	10
64	Preference-based outcome measures in cost-utility analyses. A 20-year overview. <i>International Journal of Technology Assessment in Health Care</i> , 2002 , 18, 461-6	1.8	10
63	Daily hassles score associates with the somatic and psychological health of patients with Crohn's disease. <i>Journal of Clinical Psychology</i> , 2018 , 74, 969-988	2.8	9
62	Impact of a financial risk-sharing scheme on budget-impact estimations: a game-theoretic approach. <i>European Journal of Health Economics</i> , 2014 , 15, 553-61	3.6	9
61	Does framing of cancer survival affect perceived value of care? A willingness-to-pay survey of US residents. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2013 , 13, 513-22	2.2	8
60	Estimating the budget impact of new technologies added to the National List of Health Services in Israel: stakeholders' incentives for adopting a financial risk-sharing mechanism. <i>Health Policy</i> , 2009 , 89, 78-83	3.2	8
59	Does adjusting for health-related quality of life matter in economic evaluations of cancer-related interventions?. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2011 , 11, 113-9	2.2	8
58	Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) statement: updated reporting guidance for health economic evaluations.. <i>BMJ, The</i> , 2022 , 376, e067975	5.9	8
57	Simple pain measures reveal psycho-social pathology in patients with Crohn's disease. <i>World Journal of Gastroenterology</i> , 2017 , 23, 1076-1089	5.6	8
56	Decisions to adopt new technologies at the hospital level: insights from Israeli medical centers. <i>International Journal of Technology Assessment in Health Care</i> , 2005 , 21, 219-27	1.8	8
55	Health-Related Utility Weights in a Cohort of Real-World Crohn's Disease Patients. <i>Journal of Crohn's and Colitis</i> , 2015 , 9, 1138-45	1.5	7
54	Early Atrial Fibrillation During Acute Myocardial Infarction May Not Be an Indication for Long-Term Anticoagulation. <i>Angiology</i> , 2020 , 71, 559-566	2.1	7
53	Which is more valuable, longer survival or better quality of life? Israeli oncologists' and family physicians' attitudes toward the relative value of new cancer and congestive heart failure interventions. <i>Value in Health</i> , 2013 , 16, 842-7	3.3	7
52	Oncologists' and family physicians' views on value for money of cancer and congestive heart failure care. <i>Israel Journal of Health Policy Research</i> , 2013 , 2, 44	1.7	7
51	Determinants of Cost-Related Nonadherence to Medications among Chronically Ill Patients in Maccabi Healthcare Services, Israel. <i>Value in Health Regional Issues</i> , 2014 , 4, 41-46	1.6	7
50	Financial risk-sharing in updating the National List of Health Services in Israel: stakeholders' perceived interests. <i>Value in Health</i> , 2012 , 15, 737-42	3.3	7
49	Do the benefits of new technology outweigh the costs?. <i>American Journal of Drug Delivery</i> , 2003 , 1, 255-266		7

48	Implantable cardioverter defibrillators in Israel: utilization and implantation trends. <i>International Journal of Cardiology</i> , 2002 , 82, 17-23	3.2	7
47	Reimbursement policies, incentives and disincentives to perform laparoscopic surgery in Israel. <i>Health Policy</i> , 2001 , 56, 49-63	3.2	7
46	Reply to Roberts et al.: CHEERS is Sufficient for Reporting Cost-Benefit Analysis, but May Require Further Elaboration. <i>Pharmacoeconomics</i> , 2015 , 33, 535-6	4.4	6
45	Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) statement: updated reporting guidance for health economic evaluations.. <i>BMC Medicine</i> , 2022 , 20, 23	11.4	6
44	Effect of threatening life experiences and adverse family relations in ulcerative colitis: analysis using structural equation modeling and comparison with Crohn's disease. <i>European Journal of Gastroenterology and Hepatology</i> , 2017 , 29, 577-586	2.2	5
43	What Is the Value of Innovative Pharmaceutical Therapies in Oncology and Hematology? A Willingness-to-Pay Study in Bulgaria. <i>Value in Health Regional Issues</i> , 2019 , 19, 157-162	1.6	5
42	Consolidated health economic evaluation reporting standards 2022 (CHEERS 2022) statement: updated reporting guidance for health economic evaluations.. <i>International Journal of Technology Assessment in Health Care</i> , 2022 , 38, e13	1.8	5
41	The 2010 expansion of activity-based hospital payment in Israel: an evaluation of effects at the ward level. <i>BMC Health Services Research</i> , 2019 , 19, 292	2.9	4
40	Budget Impact Analysis of Cancer Screening: A Methodological Review. <i>Applied Health Economics and Health Policy</i> , 2019 , 17, 493-511	3.4	4
39	Mass media effect on vaccines uptake during silent polio outbreak. <i>Vaccine</i> , 2018 , 36, 1556-1560	4.1	4
38	The case for orthopaedic medicine in Israel. <i>Israel Journal of Health Policy Research</i> , 2013 , 2, 42	1.7	4
37	Price trajectory of individual cancer drugs following launch.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 6502-6502	4	4
36	Brain-immune axis regulation is responsive to cognitive behavioral therapy and mindfulness intervention: Observations from a randomized controlled trial in patients with Crohn's disease.. <i>Brain, Behavior, & Immunity - Health</i> , 2022 , 19, 100407	5.1	4
35	Randomized Controlled Trial of Cognitive-Behavioral and Mindfulness-Based Stress Reduction on the Quality of Life of Patients With Crohn Disease. <i>Inflammatory Bowel Diseases</i> , 2021 ,	4.5	4
34	The study protocol for a randomized, controlled trial of acupuncture versus a sham procedure versus standard care alone for the treatment of delirium in acutely hospitalized older adults with a medical illness. <i>Maturitas</i> , 2019 , 124, 72-80	5	3
33	Rethinking cost-effectiveness in the era of zero healthcare spending growth. <i>International Journal for Equity in Health</i> , 2016 , 15, 33	4.6	3
32	Cost-Effectiveness of Episodic or Maintenance Infliximab Treatment Versus Standard Treatment in a Community-Based Incidence Cohort of Adult Ulcerative Colitis Patients With 10-Years Follow-up. <i>Gastroenterology</i> , 2012 , 142, S-256	13.3	2
31	Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) statement: updated reporting guidance for health economic evaluations.. <i>BMC Public Health</i> , 2022 , 22, 179	4.1	2

30	Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) statement: updated reporting guidance for health economic evaluations.. <i>BMC Health Services Research</i> , 2022 , 22, 114	2.9	2
29	Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) statement: Updated reporting guidance for health economic evaluations. <i>Health Policy OPEN</i> , 2022 , 3, 100063	1.9	2
28	Effects of Activity-Based Hospital Payments in Israel: A Qualitative Evaluation Focusing on the Perspectives of Hospital Managers and Physicians. <i>International Journal of Health Policy and Management</i> , 2021 , 10, 244-254	2.5	2
27	Characteristics and economic burden of frequent attenders with medically unexplained symptoms in primary care in Israel. <i>European Journal of General Practice</i> , 2021 , 27, 294-302	2.8	2
26	Mortality and healthcare resource utilization following acute myocardial infarction according to adherence to recommended medical therapy guidelines. <i>Health Policy</i> , 2020 , 124, 1200-1208	3.2	2
25	Using lower cost statins improves outcomes for normal cholesterol non-diabetic patients. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2017 , 17, 495-501	2.2	1
24	Healthcare-service utilization and direct costs throughout ten years following acute myocardial infarction: Soroka Acute Myocardial Infarction II (SAMI II) project. <i>Current Medical Research and Opinion</i> , 2019 , 35, 1257-1263	2.5	1
23	Direct oral anticoagulation and mortality in moderate to high-risk atrial fibrillation. <i>Heart</i> , 2019 , 105, 1487-1492	5.1	1
22	Temporal trends in healthcare resource utilization and costs following acute myocardial infarction. <i>Israel Journal of Health Policy Research</i> , 2020 , 9, 6	1.7	1
21	Lessons learned from the 2009-2010 H1N1 outbreak for the management of the 2013 silent polio outbreak. <i>BMC Infectious Diseases</i> , 2018 , 18, 241	4	1
20	Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) Statement: Updated Reporting Guidance for Health Economic Evaluations.. <i>Applied Health Economics and Health Policy</i> , 2022 , 20, 213	3.4	1
19	Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) statement: updated reporting guidance for health economic evaluations.. <i>European Journal of Health Economics</i> , 2022 , 1	3.6	1
18	The impact of a community-based heart failure multidisciplinary team clinic on healthcare utilization and costs. <i>ESC Heart Failure</i> , 2021 ,	3.7	1
17	Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) Statement: Updated Reporting Guidance for Health Economic Evaluations.. <i>Journal of Medical Economics</i> , 2022 , 25, 1-7	2.4	1
16	Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) Statement: Updated Reporting Guidance for Health Economic Evaluations.. <i>Pharmacoeconomics</i> , 2022 , 1	4.4	1
15	The impact of gender on early scientific publication and long-term career advancement in Israeli medical school graduates. <i>BMC Medical Education</i> , 2021 , 21, 163	3.3	1
14	Risk sharing or risk shifting? On the development of patient access schemes in the process of updating the national list of health services in Israel. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2019 , 19, 749-753	2.2	1
13	Normative data for the Brief Symptom Inventory for patients with Crohn's disease. <i>Psychology and Health</i> , 2021 , 1-12	2.9	1

12	Sex and Ethnic Disparities in Health-Related Outcomes Following Acute Myocardial Infarction in Israel. <i>Israel Medical Association Journal</i> , 2020 , 22, 303-309	0.9	1
11	Standardization of a Developmental Milestone Scale Using Data From Children in Israel.. <i>JAMA Network Open</i> , 2022 , 5, e222184	10.4	1
10	Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) statement: updated reporting guidance for health economic evaluations.. <i>Journal of Managed Care & Specialty Pharmacy</i> , 2022 , 28, 146-155	1.9	0
9	Factors Associated With Off-Label Oncology Prescriptions: The Role of Cost and Financing in a Universal Healthcare System. <i>Frontiers in Pharmacology</i> , 2021 , 12, 754390	5.6	0
8	Price trajectories assessment for Medicare Part B generic anti-cancer drugs.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 6624-6624	2.2	0
7	Note from the Editors. <i>Value in Health Regional Issues</i> , 2013 , 2, 328	1.6	
6	Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) statement: updated reporting guidance for health economic evaluations.. <i>Journal of Managed Care & Specialty Pharmacy</i> , 2022 , 1-10	1.9	
5	Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) statement: updated reporting guidance for health economic evaluations.. <i>MDM Policy and Practice</i> , 2022 , 7, 23814683211061097	1.5	
4	Economic considerations of drug-eluting stents 2005 , 233-245		
3	Factors associated with off-label (OL) drug use in oncology: The role of cost and financing in a universal healthcare system.. <i>Journal of Clinical Oncology</i> , 2021 , 39, e18825-e18825	2.2	
2	Prospects of off-label (OL) drug use in oncology: Identifying predicting variables for registration and universal healthcare reimbursement.. <i>Journal of Clinical Oncology</i> , 2021 , 39, e18842-e18842	2.2	
1	It probably worked: a Bayesian approach to evaluating the introduction of activity-based hospital payment in Israel.. <i>Israel Journal of Health Policy Research</i> , 2022 , 11, 8	1.7	